Latest news from KaloBios Pharmaceuticals, Inc. on Newswise en-us Copyright 2024 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/kalobios-kb001-anti-pseudomonas-antibody-study-published-in-pediatric-pulmonology/?sc=rsin /articles/kalobios-kb001-anti-pseudomonas-antibody-study-published-in-pediatric-pulmonology/?sc=rsin Wed, 18 Sep 2013 16:00:00 EST KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) today announced the publication of Phase 1 study results for KB001, a first generation, anti-Pseudomonas aeruginosa (Pa) type III secretion system (TTSS) antibody, for use in patients with cystic fibrosis (CF). Data from this initial single dose clinical study supports the continuation of KaloBios' ongoing Phase 2 study of KB001-A, a second generation, anti-TTSS antibody in CF patients with chronic Pa infections. KaloBios Pharmaceuticals, Inc.